In-depth analysis of the current status and future potential of the marketed antidiabetic drug classes. Drug classes covered include sulfonylureas, biguanides, insulin, TZDs, AGIs, prandial glucose regulators and Incretin Mimetics.

Overview and analysis of the antihormonal therapy cancer brands in each of the seven major markets based on 2007 sales. Includes forecasts to 2017 in light of key events set to influence product sales.

With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil’s Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 200

Sales of the Top 20 cancer therapy brands in each of the seven major markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of 6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to become part of the Top 20 cancer t

Overview and analysis of the cytotoxic therapy cancer brands in each of the seven major markets based on 2007 sales. Includes forecasts to 2017 in light of key events set to influence product sales.

The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is stil

Critical evaluation and ten year forecast of hepatis B market, including antivirals and immunomodulators. Assessment of prophylactic and therapeutic vaccines and their commercial potential.

Overview and analysis of the 20 leading cancer therapy brands in each of the seven major markets based on 2007 sales. Includes forecasts to 2017 in light of key events set to influence product sales and an in-depth review of market dynamics.

Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of produc

This report provides full analysis of the current and future infertility drug market, with indication-specific forecasts to 2016 for marketed and key pipeline drugs. Analysis is supplemented with opinion leader comment

Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy. While the antihormonal th

Analysis of the commercial landscape for pharmacological therapies for the major Herpes-family viruses as well as an assessment of non-vaccine human papilloma virus treatments, including 2007 IMS sales data and 10 year sales forecast for the 7 MM

Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major marke

Analysis of the competitive landscape for novel agents, across seven major markets. This includes the threats to currently marketed drugs, in terms of loss of market exclusivity and a predictive evaluation of loss of market share to novel agents.

The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS bl

The autoimmune disease market will be rapidly growing due to a high number of competitive brands currently on the market and a full pipeline. Company strategies include expanding the treatment algorithm by pursuing approval for ’early’ dise

Assessment and forecast for marketed and late-stage development antiretrovirals in the 7MM, including a snapshot of ROW snapshot and a case study on the Canadian market, which surpasses Japan’s in size for this indication.

Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.

A total of 11 companies make up the top five across each of the four ID sectors, their core competencies ranging from a single disease area to generics prowess, producing a comprehensive portfolio to providing a specific offerings corresponding to high

The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near t

Overview and analysis of the targeted therapy cancer brands in each of the seven major markets based on 2007 sales. Includes forecasts to 2017 in light of key events set to influence product sales.

Datamonitor expects the antihypertensive market to exceed $50bn by 2014 across the seven major markets, with novel treatments and the market-leading ARBs delivering much of this value. However, significant hurdles exist, and pharmaceutical companies ne

Over the next 10 years a significant number of key oncology products, some with blockbuster status, will lose patent protection, thus exposing billions of dollars to generic erosion. While obviously a major threat to the key pharmaceutical players and

The antidyslipidemics market is driven by the statins, which account for 87% of it. However, as many statins are expected to face patent expiry in the coming decade their role is expected to change from a driver to that of almost a resistor. Manufactur

The global Rheumatoid Arthritis (RA) market has experienced extraordinary growth over the last decade. This market valued at $4.14 billion in 2004, shows no hint of decline. The explosion in new disease modifying drugs since the late 1990`s has resulte

There is a positive outlook for the respiratory market over the next five years, which will experience a sustained period of growth driven by the expansion of sales in existing classes, the launch of major new products, and the results from several lan

The diabetes epidemic has contributed to the expansion of the antidiabetics market in the past few years, and with prevalence increasing, this trend is set to continue. However, the highest selling drug classes in the market (sulfonylureas and biguanid

Alzheimer’s patients remain poorly treated and are growing in number. Currently, cholinesterase inhibitors and the more recent NMDA-receptor antagonists...